-
Featured
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy
Research by Massachusetts General Hospital Cancer Center oncologists suggests gene profiling of tumors from patients with muscle-invasive bladder cancer can guide rational selection of those who will benefit most from bladder-preserving trimodality therapy.
Radiation Oncology contributors
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy -
Jason A. Efstathiou, MD, DPhil
Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic
Recent Article
Gene Profiling of Bladder Tumors Shows Promise for Identifying Candidates for Trimodality Therapy -
Theodore Sunki Hong, MD
Director, Gastrointestinal Service, Department of Radiation Oncology, Associate Clinical Director, Department of Radiation Oncology
-
William Shipley, MD
Andres Soriano Distinguished Professor of Radiation Oncology, Harvard Medical School
Recent Article
Alternative Chemoradiation Regimen of Trimodal Therapy Found Effective for Muscle-invasive Bladder Cancer
Mass General Department of Radiation Oncology
The Department of Radiation Oncology combines clinical expertise, compassionate care, and advanced radiation therapies to deliver the safest, most effective treatments for cancer and benign tumors.
